同种异体椎体黏附间充质基质细胞促进糖尿病小鼠肢体缺血模型的肌肉恢复
本研究在单侧股动脉结扎的雄性多基因糖尿病TALLYHO小鼠中,于结扎后7天向缺血肢体股薄肌注射人同种异体椎体黏附间充质基质细胞(vBA-MSC),评估其促进肢体灌注和肌肉恢复的效果。结果显示,与载体对照组相比,治疗组小鼠纤维化减少、灌注增加、肌扭矩增加和血管新生。PCR分析显示注射后7天和30天MyoD1(P=0.03)、MyH3(P=0.008)、VEGF-A(P=0.002;P=0.004)、IL-10(P<0.001)、Foxp3(P=0.04)和Mrc1(CD206)(P=0.02)表达上调。结论认为人同种异体vBA-MSC改善缺血性肌肉损伤并挽救肌肉功能,小鼠模型结果将支持进一步研究开发糖尿病CLTI患者的潜在疗法。
要点
- 糖尿病CLTI小鼠模型中,缺血肢体注射vBA-MSC较载体对照显示纤维化减少、灌注和肌扭矩增加及血管新生。
- 注射后7天和30天,MyoD1(P=0.03)、MyH3(P=0.008)、VEGF-A(P=0.002;P=0.004)、IL-10(P<0.001)、Foxp3(P=0.04)和Mrc1(P=0.02)mRNA表达上调。
- 作者认为这些小鼠模型结果将支持进一步研究开发糖尿病CLTI患者的潜在疗法。
核心结论
- 这些发现表明人同种异体vBA-MSC改善缺血性肌肉损伤并挽救肌肉功能。
- 这些小鼠模型结果将支持进一步研究开发糖尿病CLTI患者的潜在疗法。
研究设计与样本
- 在雄性多基因糖尿病TALLYHO小鼠中通过单侧股动脉结扎建立CLTI小鼠模型。
- 治疗组小鼠在结扎后7天向缺血肢体股薄肌注射vBA-MSC。
- 死后评估腓肠肌或胫骨肌的纤维化(胶原染色)、毛细血管密度(免疫组化)和mRNA(定量实时PCR)。
- 采用激光多普勒灌注成像和足底屈曲肌肉测试量化肢体灌注和肌肉功能变化。
主要发现
- 与载体对照组相比,治疗组小鼠显示肌肉恢复指标,包括纤维化减少、灌注增加、肌扭矩增加和血管新生。
- 注射vBA-MSC后7天和30天肌肉PCR分析显示MyoD1(P=0.03)和MyH3(P=0.008)mRNA表达上调,代表肌肉再生。
- VEGF-A(P=0.002;P=0.004)表达上调,提示血管新生。
- IL-10(P<0.001)、T调节细胞标志物Foxp3(P=0.04)和M2偏向巨噬细胞标志物Mrc1(CD206)(P=0.02)表达上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic limb-threatening ischemia (CLTI) carries a significant risk for amputation, especially in diabetic patients with poor options for revascularization. Phase I trials have demonstrated efficacy of allogeneic mesenchymal stromal cells (MSC) in treating diabetic CLTI. Vertebral bone-adherent mesenchymal stromal cells (vBA-MSC) are derived from vertebral bodies of deceased organ donors, which offer the distinct advantage of providing a 1,000x greater yield compared to that of living donor bone aspiration. This study describes the effects of intramuscular injection of allogenic vBA-MSC in promoting limb perfusion and muscle recovery in a diabetic CLTI mouse model. METHODS: A CLTI mouse model was created through unilateral ligation of the femoral artery in male polygenic diabetic TALLYHO mice. The treated mice were injected with vBA-MSC into the gracilis muscle of the ischemic limb 7 days post ligation. Gastrocnemius or tibialis muscle was assessed postmortem for fibrosis by collagen staining, capillary density via immunohistochemistry, and mRNA by quantitative real-time polymerase chain reaction (PCR). Laser Doppler perfusion imaging and plantar flexion muscle testing (MT) were performed to quantify changes in limb perfusion and muscle function. RESULTS: Compared to vehicle (Veh) control, treated mice demonstrated indicators of muscle recovery, including decreased fibrosis, increased perfusion, muscle torque, and angiogenesis. PCR analysis of muscle obtained 7 and 30 days post vBA-MSC injection showed an upregulation in the expression of MyoD1 (P = 0.03) and MyH3 (P = 0.008) mRNA, representing muscle regeneration, vascular endothelial growth factor A (VEGF-A) (P = 0.002; P = 0.004) signifying angiogenesis as well as interleukin (IL-10) (P < 0.001), T regulatory cell marker Foxp3 (P = 0.04), and M2-biased macrophage marker Mrc1 (CD206) (P = 0.02). CONCLUSIONS: These findings indicate human allogeneic vBA-MSC ameliorate ischemic muscle damage and rescue muscle function. These results in a murine model will enable further studies to develop potential therapies for diabetic CLTI patients.
引用
- Madison MK, Doiron TS, Stashevsky J, et al. Allogenic Vertebral Body Adherent Mesenchymal Stromal Cells Promote Muscle Recovery in Diabetic Mouse Model of Limb Ischemia. Ann Vasc Surg. 2024. PMID: 39343376. doi:10.1016/j.avsg.2024.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。